跳至主要内容
临床试验/NCT04162483
NCT04162483Unknown不适用

Safety and Performance of the Neuroform Atlas™ Stent System in Patients Requiring Stent Assisted Intracranial Aneurysm Treatment in France - A National, Retrospective Multi-center Registry

Stryker Neurovascular1 个研究点 分布在 1 个国家目标入组 310 人开始时间: 2019年11月19日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
310
试验地点
1
主要终点
permanent morbidity and mortality rate

研究概览

简要总结

The objective of this retrospective study is to describe in real-life settings the clinical practice, utilization and the treated population outcomes at 1-year (12-16 months) follow-up at selected, representative centers in France.

详细描述

This proposed ATLAS FR study will be a retrospective review conducted to expand our knowledge of the clinical outcomes in subjects treated in France between 01 February 2017 and 01 March 2018.

This will provide a comprehensive data set that is specifically representative of the Atlas stent use in France.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient who had undergone a stent assisted intracranial aneurysm coiling with Neuroform Atlas for the treatment of intracranial aneurysm(s) between 1st Feb 2017 and 1st March 2
  • Patient and/or their representative have/has received the written information concerning the study and not expressed opposition to the collection of his data

排除标准

  • 未提供

结局指标

主要结局

permanent morbidity and mortality rate

时间窗: up to 12-16 months post-procedure

any major ipsilateral stroke or neurological death

次要结局

  • Retreatment(up to 12-16 months)
  • AEs and device malfunctions(peri-procedure)
  • Subarachnoid hemorrhage (SAH)(Up to 12-16 months)
  • Aneurysm rupture/re-rupture(Up to 12-16 months)
  • SAEs resulting in neurological death(Up to 12-16 months)
  • Efficacy Endpoint with mRS(immediately post-procedure and at 12-16 months post procedure)
  • device-related SAEs(Up to 12-16 months)

研究者

发起方
Stryker Neurovascular
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验